Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.
Improving the clinical outcomes of stroke patients depends on the adoption of proven new therapies throughout the broader medical community. Approximately 1% of stroke patients in community settings are receiving tissue plasminogen activator (tPA) therapy 12 years after US Food and Drug Administration approval. Knowledge translation, the process by which the results of clinical investigations are adopted by clinicians and incorporated into routine practice, is important but often overlooked. This article reviews the history of tPA use in stroke as a case study of a breakdown of knowledge translation in emergency medicine. It reviews knowledge translation concepts and theory and explores practical community-academic collaborative methods based on these tenets to enhance acute stroke care delivery in the community setting.
Scott
Phillip A
PA
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI 48106-0381, USA. phlsctt@med.umich.edu
D002983:Clinical Competence; D002985:Clinical Protocols; D003419:Crisis Intervention; D017277:Drug Approval; D004502:Education, Medical, Continuing; D019317:Evidence-Based Medicine; D030141:Feedback, Psychological; D006801:Humans; D007396:Internship and Residency; D017410:Practice Guidelines as Topic; D012151:Resuscitation / Q000193:education; D020377:Self Efficacy; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D010959:Tissue Plasminogen Activator